Researchers search for treatments for thrombocytopenia
Michigan Medicine researchers are partnering with industry and the National Institutes of Health in their quest to help patients with thrombocytopenia, a low blood platelet count.
Mike Holinstat, Ph.D., is leading this effort to find better treatments for patients who are dealing with heparin-induced thrombocytopenia and thrombosis.
It’s the next step for the Holinstat lab in determining how best to help these patients.
“We have led the field in demonstrating the importance of the platelet enzyme 12-lipoxygenase in regulating platelet activation, clot formation and occlusive clotting in the vessel known as thrombosis,” said Holinstat, associate professor of internal medicine, pharmacology and surgery at the U-M Medical School.
“Unlike current therapeutic drugs targeting the coagulation pathway that often results in increased risk in bleeding, targeting 12-lipoxygense has recently been demonstrated by the Holinstat research group to effectively inhibit platelet activation without increasing the risk for bleeding,” he added. “Targeting 12-lipoxygenase for treatment of heparin-induced thrombocytopenia may represent a new class of therapeutics for treating this debilitating disease with limited risk for bleeding.”
The National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI) recently awarded VERALOX Therapeutics, a small molecule drug discovery and development company, a $319,133 Small Business Innovation Research grant for the project.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.